Stockholders Equity (Narrative) (Details) $ / shares in Units, $ in Millions					12 Months Ended
	Mar. 31, 2022 USD ($) shares	Feb. 09, 2022 USD ($) tranche $ / shares shares	Oct. 28, 2021 USD ($) $ / shares shares	Jan. 26, 2021 $ / shares shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Class of Stock [Line Items]
Common stock, shares authorized					217,000,000	217,000,000
Proceeds from issuance of private placement | $		$ 45.0
Warrant expiration term					5 years
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share | $ / shares			$ 3.30
Proceeds from equity offerings, gross | $			$ 7.0
Common Stock [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)					9,000,000	8,275,060
Common Stock Subject to Mandatory Redemption [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)				6,153,847
Shares Issued, Price Per Share | $ / shares				$ 3.25
Exercise price of warrants | $ / shares				$ 3.25
Warrants and Rights Subject to Mandatory Redemption [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				6,153,847
Cystic Fibrosis Foundation [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)			909,091
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)		9,000,000	1,212,122
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,500,000
Exercise price of warrants | $ / shares		$ 5.00
Number of tranches | tranche		2
Proceeds from issuance of common stock and warrants | $		$ 18.1
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement First Tranche [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)		3,614,792
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,807,396
Proceeds from issuance of common stock and warrants | $		$ 18.1
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement Second Tranche [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)	5,385,208
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,692,604
Proceeds from issuance of common stock and warrants | $	$ 26.9